WORLD
BUSINESS
SPORTS
TECHNOLOGY
社会
政治
国際
経済
テクノロジー
スポーツ
エンターテイメント
科学
twitter hashtag summary
twitter trend
speech separation
large number Retweet
talking summarization
alarming description
real time translation turndown translation
|
|
|
. .
an options trader made a bet on a steep climb in human genome sciences through year's end t thursday , the trader stood to profit nearly $3.5 million , as the biotech company's shares surged after news of an unsolicited takeover bid from glaxosmithkline .
選択貿易業者は年の端t木曜日、ほぼ$3.5百万を利益を得るために立った貿易業者を通して人間のゲノム科学の急な上昇でバイオテクノロジーの会社株式がglaxosmithklineからのおせっかいなテイクオーバー・ビッドのニュースの後で波立ったので賭を作った。
britain's biggest drugs firm , glaxosmithkline , yesterday stormed ahead with its $2.6bn (£1.6bn) hostile takeover of unsolicited states biotech human genome sciences , waving aside the board to take its bid direct to shareholders .
選択貿易業者は年の端t木曜日、ほぼ$3.5百万を利益を得るために立った貿易業者を通して人間のゲノム科学の急な上昇でバイオテクノロジーの会社株式がglaxosmithklineからのおせっかいなテイクオーバー・ビッドのニュースの後で波立ったので賭を作った。
an options trader made a bet on a steep climb in human genome sciences through year's end t thursday , the trader stood to profit nearly $3.5 million , aside the biotech company's shares surged after news of an unsolicited takeover bid from glaxosmithkline .
選択貿易業者は年の端t木曜日、ほぼ$3.5百万を利益を得るために立った貿易業者を通して人間のゲノム科学の急な上昇でバイオテクノロジーの会社株式がglaxosmithklineからのおせっかいなテイクオーバー・ビッドのニュースの後で波立ったので賭を作った。
britain's biggest drugs firm , glaxosmithkline , yesterday stormed ahead with its $2.6bn (£1.6bn) hostile takeover of unsolicited states biotech human genome sciences , waving aside the board to take its bid direct to shareholders .
. .
glaxosmithkline launched an unsolicited $2.6 billion offer for longtime research partner human genome sciences , making a bet on the sales prospects of several drugs the companies are developing or marketing together .
glaxosmithkline turned hostile against its long-term partner human genome sciences yesterday , revealing it has approached the us-based biotech with a $2.6bn (£1.6bn) offer that hgs rejected .
glaxosmithkline's $2.6bn offer for human genome sciences has been rejected after the us firm said the offer was not enough .
Generated 2012-5-14_13:25
|
|
|
|
|
